124 related articles for article (PubMed ID: 33809981)
1. Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.
Gossel LDH; Heim C; Pfeffermann LM; Moser LM; Bönig HB; Klingebiel TE; Bader P; Wels WS; Merker M; Rettinger E
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809981
[TBL] [Abstract][Full Text] [Related]
2. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
Heim C; Hartig L; Weinelt N; Moser LM; Salzmann-Manrique E; Merker M; Wels WS; Tonn T; Bader P; Klusmann JH; van Wijk SJL; Rettinger E
Mol Ther Oncol; 2024 Jun; 32(2):200802. PubMed ID: 38706988
[TBL] [Abstract][Full Text] [Related]
4. Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.
Shalaby N; Xia Y; Kelly JJ; Sanchez-Pupo R; Martinez F; Fox MS; Thiessen JD; Hicks JW; Scholl TJ; Ronald JA
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38722382
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
6. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma.
Kubo H; Yagyu S; Nakamura K; Yamashima K; Tomida A; Kikuchi K; Iehara T; Nakazawa Y; Hosoi H
Mol Ther Oncolytics; 2021 Mar; 20():646-658. PubMed ID: 33816783
[TBL] [Abstract][Full Text] [Related]
7. Surface expression of the immunotherapeutic target G
Wiebel M; Kailayangiri S; Altvater B; Meltzer J; Grobe K; Kupich S; Rossig C
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1394. PubMed ID: 33811471
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
9. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
10. Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells.
Tay JCK; Wang J; Du Z; Ng YY; Li Z; Ren Y; Zhang C; Zhu J; Xu XH; Wang S
Mol Ther Methods Clin Dev; 2021 Jun; 21():107-120. PubMed ID: 33816644
[TBL] [Abstract][Full Text] [Related]
11. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
[TBL] [Abstract][Full Text] [Related]
12. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.
Kang CH; Kim Y; Lee SM; Choi SU; Park CH
Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386
[TBL] [Abstract][Full Text] [Related]
13. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
[TBL] [Abstract][Full Text] [Related]
14. Proliferation of Highly Cytotoxic Human Natural Killer Cells by OX40L Armed NK-92 With Secretory Neoleukin-2/15 for Cancer Immunotherapy.
Guo M; Sun C; Qian Y; Zhu L; Ta N; Wang G; Zheng J; Guo F; Liu Y
Front Oncol; 2021; 11():632540. PubMed ID: 33937033
[TBL] [Abstract][Full Text] [Related]
15. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.
Hagelstein I; Lutz MS; Schmidt M; Heitmann JS; Malenke E; Zhou Y; Clar KL; Kopp HG; Jung G; Salih HR; Märklin M; Hinterleitner C
Front Immunol; 2021; 12():653081. PubMed ID: 33936075
[TBL] [Abstract][Full Text] [Related]
16. Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies.
St-Pierre F; Bhatia S; Chandra S
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33924213
[TBL] [Abstract][Full Text] [Related]
17. Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer.
Cutmore LC; Marshall JF
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923528
[TBL] [Abstract][Full Text] [Related]
18. Sarcoma IL-12 overexpression facilitates NK cell immunomodulation.
Rademacher MJ; Cruz A; Faber M; Oldham RAA; Wang D; Medin JA; Schloemer NJ
Sci Rep; 2021 Apr; 11(1):8321. PubMed ID: 33859303
[TBL] [Abstract][Full Text] [Related]
19. Structural Determinants of Chimeric Antigen Receptor Design.
Abdo L; Aragão EA; Bonamino M
Crit Rev Immunol; 2021; 41(1):89-104. PubMed ID: 33822527
[TBL] [Abstract][Full Text] [Related]
20. Current Headway in Cancer Immunotherapy Emphasizing the Practice of Genetically Engineered T Cells to Target Selected Tumor Antigens.
Ray SK; Mukherjee S
Crit Rev Immunol; 2021; 41(1):23-40. PubMed ID: 33822523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]